TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Coagulation data (Thromboelastography, Laboratory)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: TOF0.9 time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of clinico-pathological remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Survival rate of primary liver cancer
Endpoint domain: Mortality/survival
Primary endpoint: Incidence of complications of primary liver cancer
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in Electrocardiogram Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Changes in Vital Signs Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence rate of major adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Decision quality
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Administration (injection) site reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in safety laboratory parameters described by frequency and severity grade
Endpoint domain: Adverse events/effects
Primary endpoint: Liquid Intake-Urine Excretion Tracking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Concentration of Plasma Free Fatty Acids (FFA, mmol/L)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of Plasma Glucose (mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of Plasma Insulin (mcU/ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Concentration of Plasma Triglycerides (mg/dl)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in parental competence
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Completion of Tele-HS screen
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Rankin Score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: gene expression profiling
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-Reported Smoking Cessation
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Completion of Breath Sample Submissions
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Composite of non-fatal stroke, non-fatal myocardial infarction or death from any cardiovascular cause
Endpoint domain: Mortality/survival
Primary endpoint: Composite of new or substantially worsening nephropathy or microvascular eye disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Efficacy of ARAT with Hybrid-APC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: biomarkers of tumor cell proliferation and survival
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Proportion of Patients With Sterile Sputum Cultures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Resolution of Severe CDAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Relapse of CDAD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: steady state pharmacokinetics of abacavir/lamivudine
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Improvement in cardiac output
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: rate of refusal to participate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: rate of attrition
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: adherence to practice instructions
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: Rate of Participant Recruitment
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of patients with treatment failure
Endpoint domain: Mortality/survival
Primary endpoint: Contralateral regional failure
Endpoint domain: Mortality/survival
Primary endpoint: Change in value of Interleukins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in value of homocysteine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in 2-hour Postprandial Serum Glucose at Week 12 Following a Standardized Meal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change From Baseline in Fasting Serum Glucose at Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: CSF and serum concentration of ghrelin, leptin, GIP, GLP-1, amylin, PP, PYY, and insulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Protection factor against UVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Number of Participants With Discomfort
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Healthcare-Associated Infections
Endpoint domain: Adverse events/effects
Primary endpoint: Change in IDS-CR Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Positive and Negative Syndrome Scale (PANSS) Total Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Best Tumor Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of patients successfully reinfused with lymphocyte stem cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Adverse events during reinfusion
Endpoint domain: Adverse events/effects
Primary endpoint: HAM-D Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: AIMS Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of primary dysmenorrhea reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of BI 695501 in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of the BI 695501 in Plasma Over the Time Interval From 0 to 1032 Hours After Dose (AUC0-1032)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve of the BI 695501 in Plasma Over the Time Interval From 0 Extrapolated to Infinity (AUC0-infinity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change of STAI Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Behavioral measures of naloxone
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Physiological measures of naloxone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Prevalence of mastectomy and breast-conserving surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Score of neurological defect
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: 60-day Mortality
Endpoint domain: Mortality/survival
Primary endpoint: Measurement of gastric and oropharyngeal pH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Days With Dysmenorrheic Pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Corrected QT interval duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Alcohol Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Alcohol Binge Drinking Days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Standard Number of Alcohol Drinks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Resource Utilization
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Neck dysfunction index (NDI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: McGill pain questionnaire (MPQ) score
Endpoint domain: Life impact
Endpoint subdomain: Pain
Primary endpoint: comprehensive assessment questionnaire (GQOL-74) scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Urine Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine rifampin AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine isoniazid Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine isoniazid AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine pyrazinamide Cmax
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Urine pyrazinamide AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: pCRB (pathological complete response rate)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients Free From LV Lead-related Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Disease control rate (DCR) of intrahepatic lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Rate of prescriptions for a 4th or 5th line of chemotherapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Changes in wetting episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: activity of doxorubicin, cisplatin and continuous infusion of 5-fluorouracil
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: BMI Change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 95th BMI Percentile (%)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Thrombin Induced Platelet-fibrin Clot Strength (TIP-FCS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: SF-EMG Nerve conduction velocity test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Ease of recruiting
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in bout-related moderate to vigorous physical activity (MVPA)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: BOLD fMRI activity in key regions of interest (ROIs)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change From Baseline in Emotional Dyscontrol Sub-score of the EHD Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Stable Hematologic Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Rates of difficult endotracheal tube (ETT) placement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Rate of Participant Completion of Study
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Rate of Participant Satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Outcome of appointment
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Changes of airway inflammation profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: AF Predictors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Morphine used as rescue analgesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Curve (AUC 0-t) of Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline of Bone Mineral Density of the Lumbar Spine (L2-l4)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Fitness points
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Biochemical Parameters
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with abdominal aortic aneurysm detected
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Tumor status
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: VO2max (Maximal Aerobic Capacity)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of catheter-related bloodstream infection
Endpoint domain: Adverse events/effects
Primary endpoint: Change in bladder pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC Pain scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: WOMAC physical function scale
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: neonatal respiratory distress
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: CAPS scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: safety and efficacy of Real time myocardial echocardiography (RT-MCE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: IBS-SSS change
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Minimization of migration stone fragments
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Right Colon Adenoma Miss Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Right Colon Hyperplastic Polyp Miss Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change from baseline Knee injury and Osteoarthritis Outcome Score (KOOS)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: rate of major adverse cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: pain (self report)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Embryo development (blastocyst stage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Embryo development (cleavage stage)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: PCO2 Level Outside of Desired Range
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: New-Onset atrial fibrillation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Gametocyte prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of acromegaly
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: HLA haplotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum carotenoid concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: reduction in 24 hour urinary protein excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: reciprocal creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: urinary sediment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Detection of hypoperfusions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Time until the first relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Characteristics of patients diagnosed with AML
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Reflective Processes
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Reasons for Life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Alcohol Consequences
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Rollnick's Readiness Ruler
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Standardised uptake values (SUV)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative number of new gadolinium-enhancing lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Change in treatment choice due to Oncotype Test
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Overall safety assessment
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of diabetic patients undergoing cardiac surgery
Endpoint domain: Mortality/survival
Primary endpoint: Safety of darbepoetin
Endpoint domain: Adverse events/effects
Primary endpoint: Severity of IBS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Change From Baseline for Mean Reflective Total Nasal Symptom Score (rTNSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Patients With Blood Pressure < 140/90 mm Hg
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: prevalence of inherited retinal dystrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: incidence of inherited retinal dystrophy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Depression over time
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Anxiety over time
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in PTSD over time
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Pain over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Safety/Basic Needs over time
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Immigration Stability over time
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Change in Employment over time
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Global Impairment Rating
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change From Baseline Red Blood Cells (RBC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline White Blood Cells (WBC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline Platelets
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline Serum Creatinine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change From Baseline Creatinine Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: full recovery from atherosclerotic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Rate of net adverse cardiac events (NACEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Antibody Response to Varicella - Geometric Mean Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Response to Measles - Geometric Mean Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Response to Mumps - Geometric Mean Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Antibody Response to Rubella - Geometric Mean Titer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Frequency and amplitude of oscillations of electrocardiogram (ECG)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in peak to peak MEP amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Change in Forced Expiratory Volume in 1 Second
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Improvement in NAFLD Activity Score (NAS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Number of Subjects With Vaccine Response to Meningococcal Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Subjects With Any Grade 3 General (Solicited and Unsolicited) Symptoms
Endpoint domain: Adverse events/effects
Primary endpoint: isometric strength of shoulder internal and external rotators
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes